ClinicalTrials.gg
Not yet recruitingNCT06102083Updated Nov 2, 2023

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of TDI01 suspension in Idiopathic Pulmonary Fibrosis, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Not yet recruiting. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the clinical efficacy and safety of different doses of TDI01 Suspension, compared with control, for the treatment of patients with IPF.

Read the detailed description

This is a Phase II, multi-center, randomized, double-blinded, placebo-controlled clinical study to evaluate the efficacy and safety of TDI01 Suspension for the treatment of IPF. The study consists of a 4-week screening period, a 24-week treatment period, a 28-week extension period, and a 2-week safety follow-up period.

It is planned to include 120 IPF patients. All subjects will be randomized in a 1:1:1 ratio to receive a 24-week treatment with TDI01 Suspension dosage A, TDI01 Suspension dosage B, or the placebo. At Week 24, the subjects will be evaluated for the primary efficacy endpoints and subsequently enter the extension period. Subjects may continue receiving the investigational product until Week 52 at their voluntary consent.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

This study's planned enrollment of 120 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females or males aged 40 to 80 (inclusive) at the time of signing the ICF;
  2. Is willing to participate voluntarily in this clinical study and sign the ICF prior to study initiation;
  3. Diagnosed with Idiopathic Pulmonary Fibrosis (IPF) according to the principles of the 2022 ATS/ERS/JRS/ALAT clinical practice guidelines;
  4. Females or males of must agree and commit to using effective from the time of signing the ICF until 90 days after the last dose of the product;
  5. Has stable anti-fibrosis treatment for at least 12 weeks prior to Visit 1.
  6. /FVC ≥0.70 at screening;
  7. Percent predicted forced vital capacity (% FVC) ≥45% and ≤90% at screening;
  8. DLco% ( corrected) ≥30% and ≤90% at screening;
  9. Is willing and able to comply with the protocol and attend visits as assessed by the investigator.

Exclusion criteria

Exclusion Criteria

Subjects are not eligible for participation in the study if they meet any of the following exclusion criteria:

  1. Patients with interstitial lung disease caused by other known aetiology;
  2. Patients who experienced active tuberculosis infection within 12 months prior to screening, or present any bacterial, viral, parasitic, or fungal infection requiring treatment at screening;
  3. Patients with IPF significantly worsened within one month prior to randomization;
  4. Patients with range of emphysema more than that of pulmonary fibrosis as indicated by chest HRCT at screening;
  5. Patients who are expected to undergo a lung transplant during the course of the study or have an expected survival of less than 1 year;
  6. Patients who received any of the following medications within 28 days prior to randomization, such as unstable anti-fibrosis treatment, >15 mg/d prednisone or equivalent dose of other , immunomodulatory agents,strong inhibitors of ;
  7. Patients with a history of within 5 years prior to screening (except for patients with appropriately treated basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin or carcinoma in situ of the cervix);
  8. Patients with moderate to severe hepatic insufficiency ( class B or C) prior to screening;
  9. Patients with laboratory test results exceeding any of the following criteria at screening: total >1.5 x or /ALT >2 x ULN, and serum CK >2.5 x ULN;
  10. Patients with uncontrolled virus infection or virus infection at screening;
  11. Patients with a history of unstable or worsening cardiac disease within 6 months prior to screening;
  12. Patients with a family or personal history of long syndrome or QTcF >480 ms at screening;
  13. Patients with a (CLcr) \<50 mL/min at screening, calculated using the Cockcroft-Gault formula;
  14. Patients who are unable to complete the 6MWD test or PFT;
  15. Pregnant or lactating women; Further exclusion criteria apply.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental group 1

    TDI01 dose A, once daily

    Drug: TDI01 suspension

  • Experimental
    Experimental group 2

    TDI01 dose B, once daily

    Drug: TDI01 suspension

  • Placebo comparator
    Control group

    Placebo, once daily

    Drug: TDI01 suspension

Interventions

  • Experimental group 1: Drug: TDI01 suspension Administration: TDI01 suspension once daily. Experimental group 2: Drug: TDI01 suspension Administration: TDI01 suspension once daily. Control group: Drug: Placebo Administration: Placebo once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Forced Vital Capacity (FVC) (mL) at Week 24

    The mean change in FVC (ml) from baseline at week 24, measured by spirometer

    Time frame: At 24 week

Secondary outcomes

  1. Change From Baseline in FVC% Predicted

    The change in FVC as a percentage of expected value (FVC%) ffrom baseline measured by spirometer. The time points which will be measured are from baseline to Week 12, Week 24, Extension Week 32, Extension Week 40, and Extension Week 52.

    Time frame: From baseline up to week 52

  2. Proportion of Subjects with an Absolute Decrease of FVC% Predicted Greater than 10%

    The proportion of subjects with an absolute decrease of FVC% greater than 10% measured by spirometer from baseline. The time point which will be measured are from baseline to Week 24, and Extension Week 52.

    Time frame: From baseline up to week 52

  3. Change From Baseline in Diffusing Capacity (of Lung) for Carbon Monoxide (DLCO) %

    The Change of DLCO% with Hb correction measured by spirometer from baseline. The time point which will be measured are from baseline to Week 12 and Week 24.

    Time frame: From baseline up to week 24

  4. Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

    Time to first acute idiopathic pulmonary fibrosis exacerbation during the trial.

    Time frame: From baseline up to week 52

  5. Time to Disease Progression

    Time to Disease Progression during the trial. Disease progression is defined as 10% absolute decrease in FVC, lung transplant or death, whichever occurs first.

    Time frame: From baseline up to week 52

  6. Mean Change in Distance Walked in the 6-minute Walk Test (6MWT)

    The mean change in 6MWD. The time points which will be measured are from baseline to Week 12 and Week 24.

    Time frame: From baseline up to week 24

  7. The change in St.George's respiratory questionnaire(SGRQ)

    The mean change in total score of SGRQ from basline to Week 12 and Week 24. The SGRQ is a standardized self-completed questionnaire for measuring impaired health and perceived well-being in airways disease. It consists of multiple parts on different scales related to each question to assess the impact of respiration on the subject's life. A total score is ranged from 0 (no health impairment) to 100 (maximum health impairment). The lower the better.

    Time frame: From baseline up to week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Aug 2025, 20 months later.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 20 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Oct 26, 2023
StartEst.
Nov 2, 2023
Primary completionEst.
Aug 1, 2025
CompletionEst.
Mar 1, 2026
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06102083
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Nov 2, 2023 (estimated)
Primary completion
Aug 1, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Nov 2, 2023

Study contacts

Dai HuaPing, MD
Contact
daihuaping@ccmu.edu.cn
010-84206278

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TDI01

Start the discussion